Showing 1 posts of 1 posts found.
Astellas Pharma is set to acquire US-based Audentes Therapeutics in an all-cash deal valued at $3 billion in cash, it …
ProBioGen secures extended GMP authorisation for viral manufacturing facility
PlaqueTec coronary disease trial reaches 100 patients across eight NHS centres
PhaSER secures $2.7m Gates Foundation renewal for neglected disease drug research
Recruitment experts hired in search for new CGT Catapult chief
Envirogen secures place on NHS Scotland reverse osmosis framework